{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T10:43:15Z","timestamp":1698316995931},"reference-count":64,"publisher":"Akademiai Kiado Zrt.","issue":"3","license":[{"start":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T00:00:00Z","timestamp":1642291200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2022,1,16]]},"abstract":"<jats:p><jats:bold>\u00d6sszefoglal\u00f3.<\/jats:bold> A n\u00e9pess\u00e9g \u00f6reged\u00e9se, a meghat\u00e1roz\u00f3 cardiovascularis\n                    rizik\u00f3t\u00e9nyez\u0151k \u2013 mint a cukorbetegs\u00e9g \u2013 egyre nagyobb ar\u00e1ny\u00fa el\u0151fordul\u00e1sa, a\n                    cs\u00f6kken\u0151 akut cardiovascularis hal\u00e1loz\u00e1s az als\u00f3 v\u00e9gtagi ver\u0151\u00e9rsz\u0171k\u00fclet n\u00f6vekv\u0151\n                    megjelen\u00e9s\u00e9vel j\u00e1r. Ezzel egy\u00fctt szaporodnak a beavatkoz\u00e1st ig\u00e9nyl\u0151, jelent\u0151s\n                    \u00e9letmin\u0151s\u00e9g-roml\u00e1st, illetve v\u00e9gtag-vesz\u00e9lyeztetetts\u00e9get okoz\u00f3, s\u00falyosabb\n                    esetek. Ilyenkor az als\u00f3 v\u00e9gtagi revascularisatio sz\u00fcks\u00e9ge mer\u00fcl fel, ami az\n                    ut\u00f3bbi \u00e9vtizedben az endovascularis beavatkoz\u00e1sok sz\u00e1m\u00e1nak n\u00f6veked\u00e9s\u00e9hez\n                    vezetett. A beavatkoz\u00e1sok technikai sikere mellett \u00fajabb sz\u0171k\u00fcletek, elz\u00e1r\u00f3d\u00e1sok\n                    vesz\u00e9ly\u00e9vel kell sz\u00e1molni. Ennek h\u00e1tter\u00e9ben az atherosclerosis progresszi\u00f3ja\n                    mellett a beavatkoz\u00e1shoz k\u00f6thet\u0151, kontroll\u00e1lt \u00e9rfals\u00e9r\u00fcl\u00e9s induk\u00e1lta vascularis\n                    remodelling (neointima-hyperplasia), valamint thromboticus t\u00e9nyez\u0151k \u00e1llnak. Az\n                    \u00e9r-nyitvamarad\u00e1s hossz\u00fa t\u00e1v\u00fa biztos\u00edt\u00e1s\u00e1nak felt\u00e9tele a fenti folyamatok\n                    megel\u0151z\u00e9s\u00e9re alkalmazott optim\u00e1lis gy\u00f3gyszeres kezel\u00e9s. Ennek biztos\u00edt\u00e1sa\n                    elengedhetetlen a beavatkoz\u00e1st megel\u0151z\u0151en, periprocedur\u00e1lisan, majd az \u00e9rintett\n                    betegk\u00f6r hossz\u00fa t\u00e1v\u00fa gondoz\u00e1sa sor\u00e1n. A gy\u00f3gyszeres ter\u00e1pi\u00e1s lehet\u0151s\u00e9gek k\u00f6z\u00fcl\n                    az antithromboticus, antikoagul\u00e1ns ter\u00e1pi\u00e1nak kiemelt jelent\u0151s\u00e9ge van. Az ezen\n                    hat\u00e1s\u00fa gy\u00f3gyszerek alkalmaz\u00e1s\u00e1t igen neh\u00e9zz\u00e9 teszi (i) a thromboticus elz\u00e1r\u00f3d\u00e1s\n                    ki\u00fajul\u00e1sa \u00e9s a potenci\u00e1lis v\u00e9rz\u00e9s k\u00f6z\u00f6tti dinamikusan v\u00e1ltoz\u00f3 egyens\u00faly\n                    bizonytalans\u00e1ga, (ii) az egy\u00e9b t\u00e1rsbetegs\u00e9gek kapcs\u00e1n felmer\u00fcl\u0151 ter\u00e1pi\u00e1s\n                    szempontok egyidej\u0171 \u00e9rv\u00e9nyes\u00edt\u00e9se, valamint (iii) a napi ell\u00e1t\u00e1sban t\u00e1mpontot\n                    ad\u00f3 tudom\u00e1nyos bizony\u00edt\u00e9kok relat\u00edv hi\u00e1nya. Az \u00f6sszefoglal\u00f3 tanulm\u00e1ny a fenti\n                    gy\u00f3gyszerter\u00e1pi\u00e1s ter\u00fclet leg\u00fajabb eredm\u00e9nyeit k\u00eds\u00e9rli meg elemezni. Orv Hetil.\n                    2022; 163(3): 98\u2013108.<\/jats:p>\n                <jats:p><jats:bold>Summary.<\/jats:bold> The aging of the population, the increasing prevalence of\n                    important risk factors of atherosclerosis, like diabetes, and the declining\n                    mortality of acute cardiovascular conditions lead to increased peripheral\n                    arterial disease incidence. At the same time, cases showing a severe decline in\n                    quality of life or danger of limb loss get more prevalent that demands vascular\n                    interventions. In such cases, revascularization is recommended, and\n                    consequently, in the last decade, an expansion in endovascular procedures can be\n                    seen. Considering these procedures, besides a technical success, the risk of new\n                    stenosis or occlusion may be imminent. This may be accounted for the progression\n                    of atherosclerosis and the controlled vascular injury caused by the procedure\n                    itself that induces vascular remodeling (neointima hyperplasia) and thrombotic\n                    hyperactivity. The long-term vascular patency is closely associated with the\n                    success of an optimal medical treatment strategy. Its effect is considered\n                    essential prior to the endovascular procedure, perioperatively, and in the phase\n                    of long-term follow-up of the affected patients. In this scenario,\n                    antithrombotic and anticoagulant therapy regimes bear particular relevance. The\n                    use of this kind of drugs is challenged by (i) the uncertainty of dynamic\n                    changes of balance between the thrombotic reocclusion and the risk of bleeding,\n                    (ii) the interplay of treatment strategy related to concomitant diseases, (iii)\n                    the relative lack of high-level scientific pieces of evidence guiding daily\n                    routine. The narrative review makes an effort to provide new findings and an\n                    analysis of this therapeutic field. Orv Hetil. 2022; 163(3): 98\u2013108.<\/jats:p>","DOI":"10.1556\/650.2022.32336","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T22:02:31Z","timestamp":1642543351000},"page":"98-108","update-policy":"http:\/\/dx.doi.org\/10.1556\/policypage.crossmark.crossref.1","source":"Crossref","is-referenced-by-count":1,"title":["Az als\u00f3 v\u00e9gtagi endovascularis ver\u0151\u00e9r-beavatkoz\u00e1sok sor\u00e1n alkalmazott antithromboticus, antikoagul\u00e1ns ter\u00e1pia szempontjai"],"prefix":"10.1556","volume":"163","author":[{"given":"Endre","family":"Kolossv\u00e1ry","sequence":"first","affiliation":[{"name":"Szent Imre Egyetemi Oktat\u00f3k\u00f3rh\u00e1z, Angiol\u00f3gia Profil Budapest, T\u00e9t\u00e9nyi u. 12\u201316., 1115"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ildik\u00f3","family":"Szab\u00f3","sequence":"additional","affiliation":[{"name":"Szent Imre Egyetemi Oktat\u00f3k\u00f3rh\u00e1z, Angiol\u00f3gia Profil Budapest, T\u00e9t\u00e9nyi u. 12\u201316., 1115"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edit","family":"D\u00f3sa","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, V\u00e1rosmajori Sz\u00edv- \u00e9s \u00c9rgy\u00f3gy\u00e1szati Klinika, Intervenci\u00f3s Radiol\u00f3giai Tansz\u00e9k Budapest"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Csaba","family":"Csobay-Nov\u00e1k","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, V\u00e1rosmajori Sz\u00edv- \u00e9s \u00c9rgy\u00f3gy\u00e1szati Klinika, Intervenci\u00f3s Radiol\u00f3giai Tansz\u00e9k Budapest"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katalin","family":"Farkas","sequence":"additional","affiliation":[{"name":"Szent Imre Egyetemi Oktat\u00f3k\u00f3rh\u00e1z, Angiol\u00f3gia Profil Budapest, T\u00e9t\u00e9nyi u. 12\u201316., 1115"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zolt\u00e1n","family":"J\u00e1rai","sequence":"additional","affiliation":[{"name":"Szent Imre Egyetemi Oktat\u00f3k\u00f3rh\u00e1z, Kardiol\u00f3gia Profil Budapest"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","article-title":"Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis","volume":"382","author":"1 Fowkes","year":"2013","unstructured":"1 Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 2013; 382: 1329-1340.","journal-title":"Lancet"},{"key":"ref1","unstructured":"2 NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 2016; 387(10027): 1513-1530. Erratum: Lancet 2017; 389(10068): e2."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"107788","DOI":"10.1016\/j.diabres.2019.107788","article-title":"Decreasing incidence of pharmacologically treated type 2 diabetes in Hungary from 2001 to 2016: a nationwide cohort study","volume":"155","author":"3 Jermendy","year":"2019","unstructured":"3 Jermendy G, Kiss Z, Rokszin G, et al. Decreasing incidence of pharmacologically treated type 2 diabetes in Hungary from 2001 to 2016: a nationwide cohort study. Diabetes Res Clin Pract. 2019; 155: 107788.","journal-title":"Diabetes Res Clin Pract"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1161\/CIRCRESAHA.116.309115","article-title":"Decline in cardiovascular mortality: possible causes and implications","volume":"120","author":"4 Mensah","year":"2017","unstructured":"4 Mensah GA, Wei GS, Sorlie PD, et al. Decline in cardiovascular mortality: possible causes and implications. Circ Res. 2017; 120: 366-380.","journal-title":"Circ Res"},{"key":"ref4","unstructured":"5 Aboyans V, Ricco JB, Bartelink ME, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: the European Stroke Organization (ESO). The Task Force for the diagnosis and treatment of peripheral arterial diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018; 39: 763-816."},{"key":"ref5","unstructured":"6 Conte MS, Bradbury AW, Kolh P, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg. 2019; 58: S1-S109.e33. [Erratum: Eur J Vasc Endovasc Surg. 2020; 59: 492-493. Erratum: Eur J Vasc Endovasc Surg. 2020; 60: 158-159.]"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7 Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary. A report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. Circulation 2017; 135: e686-e725. Erratum: Circulation 2017; 135: e790.","DOI":"10.1161\/CIR.0000000000000501"},{"key":"ref7","unstructured":"8 Setacci C, Sirignano P, Galzerano G, et al. Endovascular first as \"preliminary approach\" for critical limb ischemia and diabetic foot. J Cardiovasc Surg. 2013; 54: 679-684."},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9 Wendt K, Kristiansen R, Krohg-S\u00f8rensen K, et al. Norwegian trends in numbers of lower extremity revascularisations and amputations including regional trends in endovascular treatments for peripheral arterial disease: a retrospective cross-sectional registry study from 2001 to 2014. BMJ Open 2017; 7: e016210.","DOI":"10.1136\/bmjopen-2017-016210"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.ejvs.2019.10.021","article-title":"Lower limb amputations and revascularisation procedures in the Hungarian population: a 14 year retrospective cohort study","volume":"59","author":"10 Kolossv\u00e1ry","year":"2020","unstructured":"10 Kolossv\u00e1ry E, Ferenci T, Kov\u00e1ts T, et al. Lower limb amputations and revascularisation procedures in the Hungarian population: a 14 year retrospective cohort study. Eur J Vasc Endovasc Surg. 2020; 59: 447-456.","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.avsg.2013.01.018","article-title":"Determinants of outcome after endovascular therapy for critical limb ischemia with tissue loss","volume":"28","author":"11 Meltzer","year":"2014","unstructured":"11 Meltzer AJ, Evangelisti G, Graham AR, et al. Determinants of outcome after endovascular therapy for critical limb ischemia with tissue loss. Ann Vasc Surg. 2014; 28: 144-151.","journal-title":"Ann Vasc Surg"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.jvs.2017.05.110","article-title":"Evolution and current use of technology for superficial femoral and popliteal artery interventions for claudication","volume":"66","author":"12 Schneider","year":"2017","unstructured":"12 Schneider PA. Evolution and current use of technology for superficial femoral and popliteal artery interventions for claudication. J Vasc Surg. 2017; 66: 916-923.","journal-title":"J Vasc Surg"},{"key":"ref12","unstructured":"13 Zain MA, Jamil RT, Siddiqui WJ. Neointimal hyperplasia. [Updated 2021 Aug 11.] In: StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL, 2021 January. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK499893\/."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2174\/187152911795945169","article-title":"Pathogenesis of neointima formation following vascular injury","volume":"11","author":"14 O'Brien","year":"2011","unstructured":"14 O'Brien ER, Ma X, Simard T, et al. Pathogenesis of neointima formation following vascular injury. Cardiovasc Hematol Disord Drug Targets 2011; 11: 30-39.","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"37","author":"15 Piepoli","year":"2016","unstructured":"15 Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016; 37: 2315-2381.","journal-title":"Eur Heart J"},{"key":"ref15","unstructured":"16 Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 140: e596-e646. Erratum: Circulation 2019; 140: e649-e650. Erratum: Circulation 2020; 141: e60. [Erratum: Circulation 2020; 141: e774.]"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.avsg.2017.05.030","article-title":"Risk factors for suboptimal utilization of statins and antiplatelet therapy in patients undergoing revascularization for symptomatic peripheral arterial disease","volume":"46","author":"17 Meltzer","year":"2018","unstructured":"17 Meltzer AJ, Sedrakyan A, Connolly PH, et al. Risk factors for suboptimal utilization of statins and antiplatelet therapy in patients undergoing revascularization for symptomatic peripheral arterial disease. Ann Vasc Surg. 2018; 46: 234-240.","journal-title":"Ann Vasc Surg"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.117.032361","article-title":"Association of statin dose with amputation and survival in patients with peripheral artery disease","volume":"137","author":"18 Arya","year":"2018","unstructured":"18 Arya S, Khakharia A, Binney ZO, et al. Association of statin dose with amputation and survival in patients with peripheral artery disease. Circulation 2018; 137: 1435-1446.","journal-title":"Circulation"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12933-020-01072-x","article-title":"Influence of preprocedural glycemic control on clinical outcomes of endovascular therapy in diabetic patients with lower extremity artery disease: an analysis from a Korean multicenter retrospective registry cohort","volume":"19","author":"19 Cha","year":"2020","unstructured":"19 Cha JJ, Kim H, Ko YG, et al. Influence of preprocedural glycemic control on clinical outcomes of endovascular therapy in diabetic patients with lower extremity artery disease: an analysis from a Korean multicenter retrospective registry cohort. Cardiovasc Diabetol. 2020; 19: 97.","journal-title":"Cardiovasc Diabetol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"255","DOI":"10.14740\/cr937","article-title":"The impact of antithrombotic regimens on clinical outcomes after endovascular intervention and bypass surgery for infrapopliteal artery disease","volume":"10","author":"20 Gupta","year":"2019","unstructured":"20 Gupta A, Lee MS, Gupta K, et al. The impact of antithrombotic regimens on clinical outcomes after endovascular intervention and bypass surgery for infrapopliteal artery disease. Cardiol Res. 2019; 10: 255-267.","journal-title":"Cardiol Res"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21 Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021; 42: 1289-1367. [Erratum: Eur Heart J. 2021; 42: 1908. Erratum: Eur Heart J. 2021; 42: 1925. Erratum: Eur Heart J. 2021; 42: 2298.]","DOI":"10.1093\/eurheartj\/ehaa909"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22 Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021; 42: 373-498. [Erratum: Eur Heart J. 2021; 42: 507. Erratum: Eur Heart J. 2021; 42: 546-547. Erratum: Eur Heart J. 2021; 42: 4194.]","DOI":"10.1093\/eurheartj\/ehaa945"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1161\/CIRCRESAHA.116.303503","article-title":"Endovascular intervention for peripheral artery disease","volume":"116","author":"Thukkani AK","year":"2015","unstructured":"23 Thukkani AK, Kinlay S. Endovascular intervention for peripheral artery disease. Circ Res. 2015; 116: 1599-613.","journal-title":"Circ Res"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24 Hicks CW, Holscher CM, Wang P, et al. Overuse of early peripheral vascular interventions for claudication. J Vasc Surg. 2020; 71: 121-130.e1.","DOI":"10.1016\/j.jvs.2019.05.005"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ejvs.2020.03.010","article-title":"Antiplatelet and anticoagulant use in randomised trials of patients undergoing endovascular intervention for peripheral arterial disease: systematic review and narrative synthesis","volume":"60","author":"25 Qureshi","year":"2020","unstructured":"25 Qureshi MI, Li HL, Ambler GK, et al. Antiplatelet and anticoagulant use in randomised trials of patients undergoing endovascular intervention for peripheral arterial disease: systematic review and narrative synthesis. Eur J Vasc Endovasc Surg. 2020; 60: 77-87.","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26 Patel IJ, Rahim S, Davidson JC, et al. Society of Interventional Radiology consensus guidelines for the periprocedural management of thrombotic and bleeding risk in patients undergoing percutaneous image-guided interventions - part II: recommendations: Endorsed by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe. J Vasc Interv Radiol. 2019; 30: 1168-1184.e1.","DOI":"10.1016\/j.jvir.2019.04.017"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.jvir.2019.04.016","article-title":"Society of Interventional Radiology consensus guidelines for the periprocedural management of thrombotic and bleeding risk in patients undergoing percutaneous image-guided interventions - part I: review of anticoagulation agents and clinical considerations: Endorsed by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe","volume":"30","author":"27 Davidson","year":"2019","unstructured":"27 Davidson JC, Rahim S, Hanks SE, et al. Society of Interventional Radiology consensus guidelines for the periprocedural management of thrombotic and bleeding risk in patients undergoing percutaneous image-guided interventions - part I: review of anticoagulation agents and clinical considerations: Endorsed by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe. J Vasc Interv Radiol. 2019; 30: 1155-1567.","journal-title":"J Vasc Interv Radiol"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28 Jaffe TA, Raiff D, Ho LM, et al. Management of anticoagulant and antiplatelet medications in adults undergoing percutaneous interventions. Am J Roentgenol. 2015; 205: 421-428. [Erratum: Am J Roentgenol. 2017; 208: 1176.]","DOI":"10.2214\/AJR.14.13342"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.jcin.2019.04.021","article-title":"Complications of peripheral vascular intervention: time to stop the bleeding","volume":"12","author":"Drachman DE","year":"2019","unstructured":"29 Drachman DE, Hawkins BM. Complications of peripheral vascular intervention: time to stop the bleeding. JACC Cardiovasc Interv. 2019; 12: 1150-1152.","journal-title":"JACC Cardiovasc Interv"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.jcin.2019.03.012","article-title":"Bleeding complications in lower-extremity peripheral vascular interventions: insights from the NCDR PVI Registry","volume":"12","author":"30 Bhardwaj","year":"2019","unstructured":"30 Bhardwaj B, Spertus JA, Kennedy KF, et al. Bleeding complications in lower-extremity peripheral vascular interventions: insights from the NCDR PVI Registry. JACC Cardiovasc Interv. 2019; 12: 1140-1149.","journal-title":"JACC Cardiovasc Interv"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31 Kansal A, Huang Z, Rockhold FW, et al. Impact of procedural bleeding in peripheral artery disease: an analysis from EUCLID trial. Circ Cardiovasc Interv. 2019; 12: e008069.","DOI":"10.1161\/CIRCINTERVENTIONS.119.008069"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMra1206531","article-title":"Management of antithrombotic therapy in patients undergoing invasive procedures","volume":"368","author":"32 Baron","year":"2013","unstructured":"32 Baron TH, Kamath PS, McBane RD. Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med. 2013; 368: 2113-2124.","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"33 Steffel","year":"2021","unstructured":"33 Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace 2021; 23: 1612-1676.","journal-title":"Europace"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1177\/1526602819866191","article-title":"A new preprocedural score to predict bleeding complications of endovascular interventions for peripheral artery disease","volume":"26","author":"34 Spiliopoulos","year":"2019","unstructured":"34 Spiliopoulos S, Tsochatzis A, Festas G, et al. A new preprocedural score to predict bleeding complications of endovascular interventions for peripheral artery disease. J Endovasc Ther. 2019; 26: 816-825.","journal-title":"J Endovasc Ther"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"35 Vivas D, Rold\u00e1n I, Ferrandis R, et al. Perioperative and periprocedural management of antithrombotic therapy: Consensus document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVEI, SECOT and AEU. Rev Esp Cardiol. (Engl ed.) 2018; 71: 553-564.","DOI":"10.1016\/j.rec.2018.01.029"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00270-013-0741-9","article-title":"Cardiovascular and Interventional Radiological Society of Europe guidelines on endovascular treatment in aortoiliac arterial disease","volume":"37","author":"Rossi M","year":"2014","unstructured":"36 Rossi M, Iezzi R. Cardiovascular and Interventional Radiological Society of Europe guidelines on endovascular treatment in aortoiliac arterial disease. Cardiovasc Intervent Radiol. 2014; 37: 13-25.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jvir.2012.02.012","article-title":"Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions","volume":"23","author":"37 Patel","year":"2012","unstructured":"37 Patel IJ, Davidson JC, Nikolic B, et al. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol. 2012; 23: 727-736.","journal-title":"J Vasc Interv Radiol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1456298","DOI":"10.1155\/2016\/1456298","article-title":"The use of heparin during endovascular peripheral arterial interventions: a synopsis","volume":"2016","author":"38 Wiersema","year":"2016","unstructured":"38 Wiersema AM, Watts C, Durran AC, et al. The use of heparin during endovascular peripheral arterial interventions: a synopsis. Scientifica (Cairo) 2016; 2016: 1456298.","journal-title":"Scientifica (Cairo)"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ejvs.2019.08.007","article-title":"No concluding evidence on optimal activated clotting time for non-cardiac arterial procedures","volume":"59","author":"39 Doganer","year":"2020","unstructured":"39 Doganer O, Wiersema AM, Scholtes V, et al. No concluding evidence on optimal activated clotting time for non-cardiac arterial procedures. Eur J Vasc Endovasc Surg. 2020; 59: 137-147.","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s00270-013-0558-6","article-title":"Periprocedural prophylactic antithrombotic strategies in interventional radiology: current practice in the Netherlands and comparison with the United Kingdom","volume":"36","author":"40 Wiersema","year":"2013","unstructured":"40 Wiersema AM, Vos JA, Bruijninckx CM, et al. Periprocedural prophylactic antithrombotic strategies in interventional radiology: current practice in the Netherlands and comparison with the United Kingdom. Cardiovasc Intervent Radiol. 2013; 36: 1477-1492.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"41 Hu Y, Liu AY, Zhang L, et al. A systematic review and meta-analysis of bivalirudin application in peripheral endovascular procedures. J Vasc Surg. 2019; 70: 274-284.e5.","DOI":"10.1016\/j.jvs.2018.12.037"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1016\/j.jacc.2015.03.567","article-title":"Bleeding avoidance strategies during percutaneous coronary interventions","volume":"65","author":"42 Singh","year":"2015","unstructured":"42 Singh M. Bleeding avoidance strategies during percutaneous coronary interventions. J Am Coll Cardiol. 2015; 65: 2225-2238.","journal-title":"J Am Coll Cardiol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/ccd.22113","article-title":"A position statement of the Society of Cardiovascular Angiography and Interventions","volume":"74","author":"43 Klein","year":"2009","unstructured":"43 Klein LW, Sheldon MW, Brinker J, et al. The use of radiographic contrast media during PCI: a focused review. A position statement of the Society of Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv. 2009; 74: 728-746.","journal-title":"Catheter Cardiovasc Interv"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"44 Valgimigli","year":"2018","unstructured":"44 Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018; 39: 213-260.","journal-title":"Eur Heart J"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"45 Robertson L, Ghouri MA, Kovacs F. Antiplatelet and anticoagulant drugs for prevention of restenosis\/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev. 2012; 2012: CD002071.","DOI":"10.1002\/14651858.CD002071.pub3"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1007\/s00330-012-2441-2","article-title":"Management of peripheral arterial interventions with mono or dual antiplatelet therapy - the MIRROR study: a randomised and double-blinded clinical trial","volume":"22","author":"46 Tepe","year":"2012","unstructured":"46 Tepe G, Bantleon R, Brechtel K, et al. Management of peripheral arterial interventions with mono or dual antiplatelet therapy - the MIRROR study: a randomised and double-blinded clinical trial. Eur Radiol. 2012; 22: 1998-2006.","journal-title":"Eur Radiol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1583\/13-4275MR.1","article-title":"Twelve-month results of a randomized trial comparing mono with dual antiplatelet therapy in endovascularly treated patients with peripheral artery disease","volume":"20","author":"47 Strobl","year":"2013","unstructured":"47 Strobl FF, Brechtel K, Schmehl J, et al. Twelve-month results of a randomized trial comparing mono with dual antiplatelet therapy in endovascularly treated patients with peripheral artery disease. J Endovasc Ther. 2013; 20: 699-706.","journal-title":"J Endovasc Ther"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1016\/j.jcin.2019.08.006","article-title":"Optimal strategy for antiplatelet therapy after endovascular revascularization for lower extremity peripheral artery disease","volume":"12","author":"48 Cho","year":"2019","unstructured":"48 Cho S, Lee YJ, Ko YG, et al. Optimal strategy for antiplatelet therapy after endovascular revascularization for lower extremity peripheral artery disease. JACC Cardiovasc Interv. 2019; 12: 2359-2370.","journal-title":"JACC Cardiovasc Interv"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ejvs.2016.12.014","article-title":"Editor\u1fbfs choice - Dual antiplatelet therapy improves outcome in diabetic patients undergoing endovascular femoropopliteal stenting for critical limb ischaemia","volume":"53","author":"49 Thott","year":"2017","unstructured":"49 Thott O, Granath F, Malmstedt J, et al. Editor\u1fbfs choice - Dual antiplatelet therapy improves outcome in diabetic patients undergoing endovascular femoropopliteal stenting for critical limb ischaemia. Eur J Vasc Endovasc Surg. 2017; 53: 403-410.","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"50 Chinai N, Ambler GK, Wardle BG, et al. Single versus dual antiplatelet therapy following peripheral arterial endovascular intervention for chronic limb threatening ischaemia: retrospective cohort study. PLoS ONE 2020; 15: e0234271.","DOI":"10.1371\/journal.pone.0234271"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"51 Soden PA, Zettervall SL, Ultee KH, et al. Dual antiplatelet therapy is associated with prolonged survival after lower extremity revascularization. J Vasc Surg. 2016; 64: 1633-1644.e1.","DOI":"10.1016\/j.jvs.2016.05.098"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"52 Wong KH, Bosanquet DC, Ambler GK, et al. The CLEAR (Considering Leading Experts\u1fbf Antithrombotic Regimes around peripheral angioplasty) survey: an international perspective on antiplatelet and anticoagulant practice for peripheral arterial endovascular intervention. CVIR Endovasc. 2019; 2: 37. [Erratum: CVIR Endovasc. 2020; 3: 87.]","DOI":"10.1186\/s42155-019-0079-8"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2174\/1570161112666141125123743","article-title":"New therapeutic effects of cilostazol in patients with ischemic disorders","volume":"13","author":"53 Biscetti","year":"2015","unstructured":"53 Biscetti F, Ferraccioli G, Flex A. New therapeutic effects of cilostazol in patients with ischemic disorders. Curr Vasc Pharmacol. 2015; 13: 399-404.","journal-title":"Curr Vasc Pharmacol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1177\/1526602818771358","article-title":"Sustained effectiveness of cilostazol after endovascular treatment of femoropopliteal lesions: midterm follow-up from the sufficient treatment of peripheral intervention by cilostazol (STOP-IC) study","volume":"25","author":"54 Soga","year":"2018","unstructured":"54 Soga Y, Hamasaki T, Edahiro R, et al. Sustained effectiveness of cilostazol after endovascular treatment of femoropopliteal lesions: midterm follow-up from the sufficient treatment of peripheral intervention by cilostazol (STOP-IC) study. J Endovasc Ther. 2018; 25: 306-312.","journal-title":"J Endovasc Ther"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.avsg.2017.05.029","article-title":"Efficacy of CilostAzol for Below-the-knee artery disease after Balloon AnGioplasty in PatiEnts with severe limb ischemia (CABBAGE Trial)","volume":"45","author":"55 Soga","year":"2017","unstructured":"55 Soga Y, Takahara M, Iida O, et al. Efficacy of CilostAzol for Below-the-knee artery disease after Balloon AnGioplasty in PatiEnts with severe limb ischemia (CABBAGE Trial). Ann Vasc Surg. 2017; 45: 22-28.","journal-title":"Ann Vasc Surg"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1177\/1358863X19838327","article-title":"Outcomes with cilostazol after endovascular therapy of peripheral artery disease","volume":"24","author":"56 Megaly","year":"2019","unstructured":"56 Megaly M, Abraham B, Saad M, et al. Outcomes with cilostazol after endovascular therapy of peripheral artery disease. Vasc Med. 2019; 24: 313-323.","journal-title":"Vasc Med"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1007\/s13300-020-00860-8","article-title":"Long-term cilostazol treatment and predictive factors on outcomes of endovascular intervention in patients with diabetes mellitus and critical limb ischemia","volume":"11","author":"57 Lee","year":"2020","unstructured":"57 Lee CY, Wu TC, Lin SJ. Long-term cilostazol treatment and predictive factors on outcomes of endovascular intervention in patients with diabetes mellitus and critical limb ischemia. Diabetes Ther. 2020; 11: 1757-1773.","journal-title":"Diabetes Ther"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"58 Desai K, Han B, Kuziez L, et al. Literature review and meta-analysis of the efficacy of cilostazol on limb salvage rates after infrainguinal endovascular and open revascularization. J Vasc Surg. 2021; 73: 711-721.e3.","DOI":"10.1016\/j.jvs.2020.08.125"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1177\/1526602818760488","article-title":"Edoxaban plus aspirin vs dual antiplatelet therapy in endovascular treatment of patients with peripheral artery disease: results of the ePAD trial","volume":"25","author":"59 Moll","year":"2018","unstructured":"59 Moll F, Baumgartner I, Jaff M, et al. Edoxaban plus aspirin vs dual antiplatelet therapy in endovascular treatment of patients with peripheral artery disease: results of the ePAD trial. J Endovasc Ther. 2018; 25: 158-168.","journal-title":"J Endovasc Ther"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"60 Bonaca","year":"2020","unstructured":"60 Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020; 382: 1994-2004.","journal-title":"N Engl J Med"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"61 Eikelboom","year":"2017","unstructured":"61 Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017; 377: 1319-1330.","journal-title":"N Engl J Med"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jacc.2021.05.003","article-title":"Total ischemic event reduction with rivaroxaban after peripheral arterial revascularization in the VOYAGER PAD trial","volume":"78","author":"62 Bauersachs","year":"2021","unstructured":"62 Bauersachs RM, Szarek M, Brodmann M, et al. Total ischemic event reduction with rivaroxaban after peripheral arterial revascularization in the VOYAGER PAD trial. J Am Coll Cardiol. 2021; 78: 317-326.","journal-title":"J Am Coll Cardiol"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.jcin.2021.01.035","article-title":"The role for combined antithrombotic therapy with platelet and coagulation inhibition after lower extremity revascularization","volume":"14","author":"63 Weissler","year":"2021","unstructured":"63 Weissler EH, Aboyans V, Bauersachs R, et al. The role for combined antithrombotic therapy with platelet and coagulation inhibition after lower extremity revascularization. JACC Cardiovasc Interv. 2021; 14: 796-802.","journal-title":"JACC Cardiovasc Interv"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ahj.2020.06.010","article-title":"Rationale and design for the study Apixaban versus clopidoGRel on a background of aspirin in patient undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trial","volume":"227","author":"64 Biagioni","year":"2020","unstructured":"64 Biagioni RB, Lopes RD, Agati LB, et al. Rationale and design for the study Apixaban versus clopidoGRel on a background of aspirin in patient undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trial. Am Heart J. 2020; 227: 100-106.","journal-title":"Am Heart J"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/163\/3\/article-p98.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/163\/3\/article-p98.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/163\/3\/article-p98.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T08:41:38Z","timestamp":1698223298000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/163\/3\/article-p98.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,16]]},"references-count":64,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.1556\/650.2022.32336","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,16]]}}}